SCHEMBL16070239

SCHEMBL16070239

CCN1CCN(c2ccc(Nc3ncc(CCc4cc(C(=O)NC)cc(OC)c4Cl)cn3)cc2OC)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FGFR3 P22607 10/20 0.51
▸ PDGFRB P09619 1/20 0.46
▸ PDGFRA P16234 1/20 0.46
▸ KCNH2 Q12809 2/20 0.45
▸ PAK1 Q13153 4/20 0.44
▸ FGFR1 P11362 1/20 0.44
▸ FGFR2 P21802 1/20 0.44
▸ FGFR4 P22455 1/20 0.44
▸ KDR P35968 1/20 0.44
▸ CHRM1 P11229 2/20 0.43
▸ CHRM5 P08912 1/20 0.43
▸ CHRM3 P20309 1/20 0.43
▸ HTR1A P08908 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ CDK4 P11802 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17470086 0.92 FGFR3 (0.60) FGFR3KCNH2PAK1FGFR1FGFR2
SCHEMBL16070344 0.91 FGFR3 (0.58) FGFR3PDGFRBPDGFRAKCNH2PAK1
SCHEMBL17470186 0.91 POLB (0.50) FGFR3PDGFRAFGFR1FGFR2FGFR4
SCHEMBL16070237 0.89 FGFR3 (0.50) FGFR3PDGFRBPDGFRAPAK1FGFR1
SCHEMBL17470059 0.85 FGFR3 (0.48) FGFR3KCNH2PAK1FGFR1FGFR2
SCHEMBL16070350 0.84 PDGFRA (0.45) FGFR3PDGFRBPDGFRAPAK1FGFR1
SCHEMBL16069704 0.84 POLB (0.49) FGFR3PDGFRAFGFR1FGFR2FGFR4
SCHEMBL17470193 0.83 FGFR3 (0.69) FGFR3KCNH2PAK1FGFR1FGFR2
SCHEMBL17469949 0.82 POLB (0.51) FGFR3PDGFRAFGFR1FGFR2FGFR4
SCHEMBL16070197 0.82 PTK2 (0.45) FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701680-B2 Pyrimidine and pyridine compounds and their usage HUTCHISON MEDIPHARMA LIMITED (CN) 2017-07-11 — — US disclosed
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2016-01-28 — — US disclosed
WO-2014139465-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE FGFR3, FGFR1, FGFR4 FGFR3 1/4885PDGFRB 20/4885PDGFRA 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback